This study, which was published in the journal of Neurology in October 2022, aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset.
Elevated tau levels were associated with MCI symptom onset if it occurred within 7 years of baseline measure, but less so if onset occurred after 7 years.
These findings confirm and extend prior results in several important ways. Across the 94 subjects who progressed from normal cognition to MCI or dementia, elevated tau levels were associated with MCI symptom onset if it occurred within 7 years of baseline measure, but less so if onset occurred after 7 years. Conversely, Aβ measures were associated with symptom onset if it occurred after, rather than before 7 years. Moreover, the associations of CSF AD biomarkers to time to MCI symptom onset are influenced by sex, baseline age, and ApoE4 genotype factors potentially affecting clinical trial enrollment and anticipated outcomes, either for amyloid-based and tau-based therapies or alternative therapeutic approaches that may use these measures as surrogate markers of treatment response.
Aβ measures were associated with symptom onset if it occurred after, rather than before 7 years
Comentarios